abacavir 🐢 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals carbocyclic nucleosides 34 136470-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 1592U89
  • abacavir
  • abacavir sulfate
  • ziagen
  • abacavir succinate
a carbocyclic nucleoside with potent selective anti-HIV activity; structure given in first source
  • Molecular weight: 286.34
  • Formula: C14H18N6O
  • CLOGP: 0.81
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 101.88
  • ALOGS: -2.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 77 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 29.93 Β΅M/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.84 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 8, 1999 EMA
Dec. 17, 1998 FDA VIIV HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 393.92 24.46 232 6900 120783 50477209
Viral mutation identified 252.27 24.46 56 7076 1573 50596419
Abortion spontaneous 236.52 24.46 116 7016 41656 50556336
Virologic failure 227.05 24.46 51 7081 1513 50596479
Hypomania 218.37 24.46 61 7071 4444 50593548
Jaundice cholestatic 210.75 24.46 61 7071 5050 50592942
Immune reconstitution inflammatory syndrome 206.16 24.46 61 7071 5455 50592537
Schizophrenia 188.52 24.46 61 7071 7336 50590656
Drug resistance 184.74 24.46 77 7055 18912 50579080
Hepatotoxicity 173.35 24.46 82 7050 27144 50570848
Pathogen resistance 153.49 24.46 49 7083 5640 50592352
Lipodystrophy acquired 132.76 24.46 32 7100 1297 50596695
Psychotic disorder 130.60 24.46 63 7069 21749 50576243
Blood bilirubin increased 126.69 24.46 70 7062 31968 50566024
Foetal exposure during pregnancy 122.73 24.46 65 7067 27294 50570698
Live birth 118.64 24.46 54 7078 16354 50581638
Premature baby 106.85 24.46 52 7080 18285 50579707
Cholelithiasis 97.93 24.46 63 7069 37910 50560082
Stillbirth 92.79 24.46 34 7098 5918 50592074
Blood HIV RNA increased 91.20 24.46 20 7112 529 50597463
CD4 lymphocytes decreased 87.70 24.46 23 7109 1316 50596676
Treatment noncompliance 85.17 24.46 53 7079 30097 50567895
Abortion induced 84.50 24.46 36 7096 9308 50588684
Pregnancy 78.54 24.46 50 7082 29527 50568465
Drug ineffective 62.85 24.46 19 7113 819314 49778678
Foetal death 53.11 24.46 25 7107 8155 50589837
Drug reaction with eosinophilia and systemic symptoms 51.58 24.46 38 7094 28386 50569606
Hepatic enzyme increased 50.29 24.46 78 7054 137302 50460690
Trisomy 21 47.67 24.46 11 7121 368 50597624
Maternal exposure during pregnancy 45.45 24.46 81 7051 159697 50438295
Infertility 42.41 24.46 11 7121 602 50597390
Hyperbilirubinaemia 40.80 24.46 22 7110 9548 50588444
Caesarean section 40.41 24.46 26 7106 15613 50582379
Ovarian failure 40.24 24.46 12 7120 1099 50596893
Astrocytoma malignant 38.89 24.46 6 7126 18 50597974
Placental insufficiency 38.55 24.46 12 7120 1269 50596723
Vomiting 38.52 24.46 147 6985 460611 50137381
Fanconi syndrome acquired 37.95 24.46 11 7121 912 50597080
Premature labour 37.07 24.46 22 7110 11454 50586538
Pain 36.67 24.46 18 7114 578885 50019107
Foetal growth restriction 36.21 24.46 18 7114 6609 50591383
Fall 36.07 24.46 3 7129 334929 50263063
Pre-eclampsia 35.72 24.46 19 7113 8025 50589967
Viral load increased 35.44 24.46 11 7121 1152 50596840
Antiviral drug level below therapeutic 34.49 24.46 6 7126 44 50597948
Drug interaction 34.06 24.46 82 7050 199539 50398453
Anaemia 32.17 24.46 93 7039 252363 50345629
Fatigue 31.68 24.46 32 7100 707569 49890423
Nephropathy toxic 30.21 24.46 17 7115 8012 50589980
Central nervous system lesion 30.15 24.46 18 7114 9471 50588521
Ultrasound scan abnormal 29.68 24.46 7 7125 258 50597734
Foetal anaemia 29.61 24.46 5 7127 30 50597962
Oligohydramnios 29.60 24.46 15 7117 5735 50592257
Isoimmune haemolytic disease 29.47 24.46 5 7127 31 50597961
Amenorrhoea 29.34 24.46 17 7115 8467 50589525
HIV infection 29.19 24.46 7 7125 277 50597715
Pleocytosis 29.03 24.46 8 7124 552 50597440
Premature delivery 28.73 24.46 25 7107 23638 50574354
HIV-associated neurocognitive disorder 28.72 24.46 6 7126 125 50597867
Lipoatrophy 28.52 24.46 7 7125 306 50597686
Mitochondrial toxicity 27.58 24.46 7 7125 351 50597641
Proteinuria 27.45 24.46 21 7111 16576 50581416
Renal tubular dysfunction 27.30 24.46 7 7125 366 50597626
Generalised anxiety disorder 26.90 24.46 10 7122 1810 50596182
Social avoidant behaviour 26.02 24.46 11 7121 2786 50595206
Pubertal failure 25.69 24.46 4 7128 13 50597979
Paraparesis 25.67 24.46 10 7122 2054 50595938
HIV wasting syndrome 25.24 24.46 4 7128 15 50597977

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 540.76 15.08 151 14861 2943 29556572
Immune reconstitution inflammatory syndrome 492.92 15.08 175 14837 7627 29551888
Mitochondrial toxicity 368.51 15.08 106 14906 2305 29557210
Virologic failure 308.57 15.08 96 14916 2751 29556764
Progressive external ophthalmoplegia 289.34 15.08 77 14935 1240 29558275
Eyelid ptosis 248.59 15.08 95 14917 5091 29554424
Viral mutation identified 208.46 15.08 69 14943 2419 29557096
Diplopia 167.06 15.08 97 14915 13421 29546094
Pathogen resistance 135.40 15.08 71 14941 8045 29551470
Lipoatrophy 104.59 15.08 28 14984 461 29559054
Drug resistance 94.32 15.08 82 14930 21458 29538057
Drug interaction 84.21 15.08 255 14757 197130 29362385
Blood HIV RNA increased 84.17 15.08 28 14984 996 29558519
CSF HIV escape syndrome 81.89 15.08 19 14993 167 29559348
Foetal exposure during pregnancy 81.39 15.08 93 14919 33774 29525741
Ophthalmoplegia 77.66 15.08 30 14982 1652 29557863
Polydactyly 77.36 15.08 27 14985 1113 29558402
HIV-associated neurocognitive disorder 76.50 15.08 20 14992 299 29559216
Exposure during pregnancy 74.16 15.08 49 14963 8505 29551010
Dyslipidaemia 73.54 15.08 43 14969 6018 29553497
Fanconi syndrome acquired 71.56 15.08 29 14983 1813 29557702
Renal impairment 65.34 15.08 134 14878 81199 29478316
Hyperlipidaemia 63.47 15.08 52 14960 12538 29546977
Hypertriglyceridaemia 62.82 15.08 42 14970 7433 29552082
Osteonecrosis 60.24 15.08 52 14960 13467 29546048
Off label use 59.53 15.08 40 14972 300760 29258755
Viral load increased 58.75 15.08 26 14986 2023 29557492
Kaposi's sarcoma 56.90 15.08 20 14992 842 29558673
Hyperlactacidaemia 55.08 15.08 27 14985 2651 29556864
CD4 lymphocytes decreased 54.76 15.08 23 14989 1575 29557940
Mitochondrial cytopathy 51.48 15.08 13 14999 168 29559347
Oral candidiasis 49.31 15.08 42 14970 10680 29548835
Pyrexia 47.63 15.08 278 14734 287344 29272171
Cachexia 47.02 15.08 33 14979 6316 29553199
Oesophageal candidiasis 46.06 15.08 27 14985 3794 29555721
Mitochondrial myopathy 45.14 15.08 12 15000 192 29559323
Multiple-drug resistance 42.95 15.08 26 14986 3874 29555641
Blood triglycerides increased 40.98 15.08 41 14971 12793 29546722
Drug ineffective 40.51 15.08 77 14935 363093 29196422
HIV infection 40.47 15.08 17 14995 1164 29558351
Fall 40.03 15.08 20 14992 177158 29382357
Meningitis cryptococcal 39.72 15.08 20 14992 2080 29557435
Cytomegalovirus chorioretinitis 39.35 15.08 23 14989 3215 29556300
Nephrolithiasis 39.31 15.08 56 14956 25278 29534237
Blood lactic acid increased 38.18 15.08 28 14984 5738 29553777
Retinal toxicity 37.04 15.08 12 15000 392 29559123
Acquired immunodeficiency syndrome 36.39 15.08 12 15000 415 29559100
Lactic acidosis 35.84 15.08 59 14953 30188 29529327
Fanconi syndrome 35.54 15.08 17 14995 1581 29557934
Nephropathy toxic 35.52 15.08 35 14977 10721 29548794
Mycobacterium avium complex infection 35.42 15.08 19 14993 2250 29557265
White matter lesion 35.10 15.08 13 14999 637 29558878
Nervous system disorder 34.19 15.08 37 14975 12637 29546878
Liver disorder 34.06 15.08 55 14957 27694 29531821
Hepatitis C 33.22 15.08 31 14981 8879 29550636
Portal hypertension 32.73 15.08 21 14991 3465 29556050
Completed suicide 32.11 15.08 4 15008 90242 29469273
HIV associated nephropathy 32.07 15.08 10 15002 288 29559227
Calculus urinary 31.06 15.08 14 14998 1137 29558378
Enterovirus infection 30.99 15.08 12 15000 665 29558850
Trisomy 21 30.57 15.08 11 15001 496 29559019
Jaundice 30.56 15.08 54 14958 29242 29530273
Bone metabolism disorder 29.59 15.08 9 15003 238 29559277
Bacterial pyelonephritis 29.41 15.08 9 15003 243 29559272
Genotype drug resistance test positive 29.39 15.08 13 14999 1010 29558505
Facial wasting 29.26 15.08 8 15004 143 29559372
Proteinuria 29.16 15.08 38 14974 15766 29543749
Human immunodeficiency virus transmission 29.13 15.08 6 15006 28 29559487
Hepatic fibrosis 29.08 15.08 19 14993 3233 29556282
Atrial fibrillation 28.63 15.08 9 15003 105637 29453878
Renal tubular disorder 28.51 15.08 21 14991 4331 29555184
Cerebral toxoplasmosis 28.30 15.08 14 14998 1402 29558113
Neonatal asphyxia 28.11 15.08 9 15003 283 29559232
Progressive multifocal leukoencephalopathy 28.10 15.08 28 14984 8691 29550824
Trimethylaminuria 27.44 15.08 5 15007 10 29559505
Treatment noncompliance 27.02 15.08 46 14966 24181 29535334
Transplant rejection 26.81 15.08 28 14984 9184 29550331
Choroiditis 26.61 15.08 12 15000 976 29558539
HIV viraemia 26.36 15.08 6 15006 48 29559467
Gene mutation 26.01 15.08 12 15000 1029 29558486
Taeniasis 25.83 15.08 6 15006 53 29559462
Primary syphilis 25.31 15.08 5 15007 18 29559497
Small for dates baby 25.11 15.08 18 14994 3561 29555954
Premature baby 25.06 15.08 37 14975 17243 29542272
Varices oesophageal 24.81 15.08 17 14995 3129 29556386
Tubulointerstitial nephritis 24.47 15.08 37 14975 17606 29541909
Pulmonary tuberculosis 24.25 15.08 19 14993 4296 29555219
Pain 24.13 15.08 31 14981 171401 29388114
Crystal urine 24.09 15.08 6 15006 73 29559442
Atrioventricular septal defect 23.98 15.08 7 15005 160 29559355
Dyspnoea 23.58 15.08 86 14926 326646 29232869
Blood uric acid increased 23.31 15.08 21 14991 5747 29553768
Hyperbilirubinaemia 23.14 15.08 33 14979 14901 29544614
Product dose omission issue 23.10 15.08 10 15002 96373 29463142
Gamma-glutamyltransferase increased 22.55 15.08 45 14967 26692 29532823
Blood insulin increased 22.44 15.08 8 15004 351 29559164
Anogenital warts 22.31 15.08 9 15003 556 29558959
Lipohypertrophy 22.14 15.08 7 15005 211 29559304
Loss of anatomical alignment after fracture reduction 21.96 15.08 4 15008 8 29559507
Subchondral insufficiency fracture 21.96 15.08 4 15008 8 29559507
Heart transplant rejection 21.88 15.08 11 15001 1140 29558375
Hepatic function abnormal 21.83 15.08 56 14956 39203 29520312
Glycosuria 21.78 15.08 11 15001 1151 29558364
Constipation 21.42 15.08 16 14996 114144 29445371
Musculoskeletal toxicity 21.41 15.08 6 15006 118 29559397
Hepatomegaly 21.37 15.08 25 14987 9292 29550223
Pneumonia 21.35 15.08 87 14925 320085 29239430
Drug abuse 21.29 15.08 7 15005 79876 29479639
Coccidioidomycosis 21.28 15.08 9 15003 627 29558888
Fracture malunion 21.06 15.08 4 15008 11 29559504
Endocardial fibroelastosis 20.57 15.08 4 15008 13 29559502
Coronary artery disease 20.53 15.08 59 14953 44131 29515384
Myocardial infarction 20.38 15.08 110 14902 110186 29449329
Pancreatic failure 20.31 15.08 9 15003 702 29558813
Post transplant distal limb syndrome 20.23 15.08 7 15005 281 29559234
Hypotension 20.05 15.08 43 14969 194311 29365204
Death 19.78 15.08 98 14914 341986 29217529
Blood bilirubin increased 19.53 15.08 49 14963 33844 29525671
Tuberculosis 19.39 15.08 21 14991 7175 29552340
Brain oedema 18.93 15.08 27 14985 12193 29547322
Blood pressure increased 18.75 15.08 7 15005 73796 29485719
Erythema elevatum diutinum 18.44 15.08 4 15008 25 29559490
Encephalitis 17.74 15.08 19 14993 6411 29553104
Pancytopenia 17.47 15.08 86 14926 83082 29476433
Glucose tolerance impaired 17.23 15.08 13 14999 2781 29556734
Hepatitis A 17.22 15.08 7 15005 441 29559074
Hepatitis D 17.15 15.08 4 15008 36 29559479
Skin test negative 16.96 15.08 4 15008 38 29559477
Ophthalmic herpes simplex 16.90 15.08 6 15006 260 29559255
Life expectancy shortened 16.60 15.08 4 15008 42 29559473
Segmented hyalinising vasculitis 16.51 15.08 4 15008 43 29559472
Congenital pigmentation disorder 16.47 15.08 3 15009 6 29559509
Pharyngitis 16.45 15.08 19 14993 6964 29552551
Lymphadenopathy 16.34 15.08 38 14974 25011 29534504
Dandy-Walker syndrome 16.17 15.08 5 15007 140 29559375
Hypophosphataemia 16.11 15.08 20 14992 7904 29551611
Herpes virus infection 16.10 15.08 12 15000 2519 29556996
Febrile neutropenia 16.08 15.08 20 14992 112220 29447295
Splenomegaly 15.85 15.08 26 14986 13253 29546262
Aspartate aminotransferase increased 15.71 15.08 66 14946 59659 29499856
Malignant neoplasm progression 15.68 15.08 9 15003 73850 29485665
Induration 15.57 15.08 8 15004 868 29558647
Fat tissue increased 15.30 15.08 6 15006 344 29559171
Normal newborn 15.27 15.08 5 15007 169 29559346
Blood alkaline phosphatase increased 15.25 15.08 40 14972 28366 29531149

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 673.18 16.24 214 17700 12256 64468562
Lipodystrophy acquired 665.88 16.24 166 17748 3861 64476957
Viral mutation identified 484.16 16.24 124 17790 3222 64477596
Virologic failure 474.96 16.24 123 17791 3343 64477475
Mitochondrial toxicity 439.55 16.24 110 17804 2596 64478222
Progressive external ophthalmoplegia 340.22 16.24 78 17836 1249 64479569
Pathogen resistance 270.11 16.24 109 17805 12434 64468384
Eyelid ptosis 248.08 16.24 95 17819 9430 64471388
Drug resistance 235.26 16.24 137 17777 34965 64445853
Exposure during pregnancy 203.13 16.24 170 17744 77505 64403313
Abortion spontaneous 186.85 16.24 105 17809 25038 64455780
Blood HIV RNA increased 171.36 16.24 46 17868 1438 64479380
Hypomania 163.90 16.24 61 17853 5593 64475225
Diplopia 159.82 16.24 97 17817 26668 64454150
Jaundice cholestatic 138.66 16.24 61 17853 8609 64472209
Schizophrenia 132.93 16.24 64 17850 11104 64469714
Hepatotoxicity 120.26 16.24 95 17819 39867 64440951
Drug interaction 114.46 16.24 286 17628 361797 64119021
CSF HIV escape syndrome 110.10 16.24 24 17890 301 64480517
Blood bilirubin increased 108.85 16.24 105 17809 57448 64423370
Lipoatrophy 108.62 16.24 27 17887 618 64480200
HIV-associated neurocognitive disorder 93.48 16.24 21 17893 305 64480513
Fanconi syndrome acquired 92.30 16.24 32 17882 2389 64478429
CD4 lymphocytes decreased 92.12 16.24 32 17882 2403 64478415
Psychotic disorder 86.82 16.24 74 17840 34504 64446314
Cholelithiasis 80.39 16.24 80 17834 45426 64435392
Ophthalmoplegia 77.75 16.24 29 17885 2673 64478145
Live birth 73.07 16.24 43 17871 11161 64469657
Hypertriglyceridaemia 73.07 16.24 43 17871 11162 64469656
Viral load increased 72.69 16.24 27 17887 2460 64478358
Pain 70.37 16.24 33 17881 553478 63927340
Dyslipidaemia 69.72 16.24 39 17875 9203 64471615
Stillbirth 69.42 16.24 29 17885 3604 64477214
Renal impairment 69.36 16.24 130 17784 134887 64345931
Abortion induced 68.21 16.24 34 17880 6354 64474464
Treatment noncompliance 66.94 16.24 71 17843 43411 64437407
Mitochondrial cytopathy 63.92 16.24 16 17898 377 64480441
Nephropathy toxic 62.26 16.24 46 17868 17468 64463350
Fall 60.91 16.24 20 17894 416806 64064012
Drug ineffective 59.16 16.24 89 17825 840158 63640660
Hyperlipidaemia 57.32 16.24 49 17865 22927 64457891
Cachexia 56.52 16.24 34 17880 9183 64471635
Pyrexia 56.25 16.24 304 17610 558340 63922478
Off label use 52.74 16.24 59 17855 632747 63848071
Retinal toxicity 52.33 16.24 18 17896 1312 64479506
Hepatic enzyme increased 51.09 16.24 112 17802 129831 64350987
Meningitis cryptococcal 50.80 16.24 22 17892 2987 64477831
Lactic acidosis 50.28 16.24 73 17841 61337 64419481
Hyperlactacidaemia 49.42 16.24 25 17889 4819 64475999
Hyperbilirubinaemia 48.41 16.24 43 17871 21162 64459656
Mitochondrial myopathy 48.17 16.24 12 17902 277 64480541
Mycobacterium avium complex infection 48.15 16.24 23 17891 3917 64476901
Blood lactic acid increased 47.87 16.24 32 17882 10369 64470449
Drug reaction with eosinophilia and systemic symptoms 46.66 16.24 66 17848 54151 64426667
Peripheral swelling 46.29 16.24 3 17911 209150 64271668
Proteinuria 45.76 16.24 47 17867 27676 64453142
Completed suicide 44.81 16.24 5 17909 224409 64256409
HIV viraemia 44.62 16.24 9 17905 75 64480743
Hepatitis C 43.87 16.24 31 17883 10984 64469834
Osteonecrosis 43.27 16.24 46 17868 28183 64452635
HIV associated nephropathy 42.76 16.24 11 17903 290 64480528
Kaposi's sarcoma 40.97 16.24 13 17901 736 64480082
Multiple-drug resistance 39.91 16.24 24 17890 6478 64474340
Calculus urinary 39.48 16.24 16 17898 1841 64478977
Brain oedema 39.32 16.24 39 17875 22036 64458782
Jaundice 38.74 16.24 57 17857 48455 64432363
Blood triglycerides increased 38.65 16.24 36 17878 18830 64461988
Renal tubular disorder 36.49 16.24 22 17892 5965 64474853
Joint swelling 35.80 16.24 8 17906 215374 64265444
Cytomegalovirus chorioretinitis 35.08 16.24 20 17894 4892 64475926
Product dose omission issue 34.96 16.24 6 17908 194741 64286077
Glycosuria 34.48 16.24 15 17899 2059 64478759
Foetal death 34.11 16.24 21 17893 5909 64474909
HIV infection 33.69 16.24 12 17902 970 64479848
Renal tubular dysfunction 33.59 16.24 11 17903 689 64480129
Central nervous system lesion 33.13 16.24 27 17887 11822 64468996
Nephrolithiasis 32.98 16.24 50 17864 43633 64437185
Pulmonary tuberculosis 32.65 16.24 22 17892 7222 64473596
Enterovirus infection 32.51 16.24 13 17901 1444 64479374
Choroiditis 32.50 16.24 12 17902 1075 64479743
Fanconi syndrome 31.79 16.24 15 17899 2486 64478332
Renal tubular necrosis 30.35 16.24 34 17880 22076 64458742
Hepatic fibrosis 30.27 16.24 19 17895 5533 64475285
Pregnancy 30.22 16.24 33 17881 20832 64459986
Bone metabolism disorder 30.00 16.24 9 17905 422 64480396
Sinusitis 29.76 16.24 3 17911 145925 64334893
Transplant rejection 29.62 16.24 30 17884 17371 64463447
Taeniasis 29.44 16.24 6 17908 53 64480765
Genotype drug resistance test positive 29.29 16.24 11 17903 1033 64479785
Atrial fibrillation 29.15 16.24 6 17908 171083 64309735
Lymphadenopathy 29.15 16.24 49 17865 46637 64434181
Pancreatitis 28.84 16.24 56 17858 59551 64421267
Dyspnoea 28.72 16.24 103 17811 718571 63762247
Primary syphilis 28.54 16.24 5 17909 17 64480801
HIV wasting syndrome 28.41 16.24 6 17908 64 64480754
Oesophageal candidiasis 28.36 16.24 21 17893 7996 64472822
Portal hypertension 28.30 16.24 19 17895 6200 64474618
Bacterial pyelonephritis 27.86 16.24 9 17905 540 64480278
White matter lesion 27.15 16.24 12 17902 1710 64479108
Constipation 27.07 16.24 15 17899 229322 64251496
Tuberculosis 26.94 16.24 25 17889 13013 64467805
Facial wasting 26.85 16.24 6 17908 85 64480733
Astrocytoma malignant 26.83 16.24 5 17909 26 64480792
Cerebral toxoplasmosis 26.48 16.24 12 17902 1814 64479004
Renal failure 26.28 16.24 110 17804 181578 64299240
Rash maculo-papular 26.28 16.24 47 17867 46979 64433839
Abdominal discomfort 26.14 16.24 9 17905 182313 64298505
Encephalitis 25.77 16.24 24 17890 12547 64468271
Oral candidiasis 25.73 16.24 32 17882 23180 64457638
Arthralgia 25.42 16.24 53 17861 442207 64038611
Gamma-glutamyltransferase increased 25.23 16.24 47 17867 48463 64432355
Coronary artery disease 24.76 16.24 53 17861 60380 64420438
Swelling 24.59 16.24 7 17907 160211 64320607
Loss of anatomical alignment after fracture reduction 24.37 16.24 4 17910 8 64480810
Nasopharyngitis 24.36 16.24 12 17902 196061 64284757
Nervous system disorder 24.29 16.24 31 17883 23047 64457771
Ovarian failure 23.89 16.24 8 17906 537 64480281
Pre-eclampsia 23.58 16.24 17 17897 6214 64474604
Vomiting 23.08 16.24 244 17670 550873 63929945
Erythema elevatum diutinum 22.53 16.24 4 17910 15 64480803
Pubertal failure 22.53 16.24 4 17910 15 64480803
Blood pressure increased 22.30 16.24 10 17904 172542 64308276
Aspartate aminotransferase increased 21.79 16.24 78 17836 119710 64361108
Meningitis tuberculous 21.67 16.24 9 17905 1102 64479716
Hepatitis 21.05 16.24 42 17872 45540 64435278
Social avoidant behaviour 20.92 16.24 14 17900 4543 64476275
Hypophosphataemia 20.83 16.24 23 17891 14697 64466121
Anogenital warts 20.78 16.24 8 17906 804 64480014
Alanine aminotransferase increased 20.74 16.24 85 17829 138946 64341872
Fatigue 20.57 16.24 123 17791 748607 63732211
Infertility 20.29 16.24 7 17907 515 64480303
Caesarean section 20.23 16.24 20 17894 11254 64469564
Breech delivery 20.21 16.24 4 17910 30 64480788
Post transplant distal limb syndrome 20.18 16.24 7 17907 523 64480295
CD4 lymphocytes increased 20.13 16.24 6 17908 275 64480543
Polydipsia 20.04 16.24 15 17899 5806 64475012
Crystal urine 19.93 16.24 5 17909 119 64480699
Hepatomegaly 19.89 16.24 24 17890 16858 64463960
Generalised anxiety disorder 19.87 16.24 10 17904 1905 64478913
Cushing's syndrome 19.55 16.24 8 17906 943 64479875
Blood uric acid increased 19.52 16.24 17 17897 8146 64472672
Ocular icterus 19.50 16.24 14 17900 5084 64475734
5'nucleotidase increased 19.49 16.24 3 17911 3 64480815
Hepatic function abnormal 19.36 16.24 50 17864 64263 64416555
New onset diabetes after transplantation 19.32 16.24 5 17909 135 64480683
Alopecia 19.31 16.24 11 17903 165679 64315139
Hepatitis D 19.27 16.24 4 17910 39 64480779
Myocardial infarction 19.18 16.24 94 17820 165727 64315091
Antiviral drug level below therapeutic 19.09 16.24 4 17910 41 64480777
Therapeutic product effect incomplete 18.98 16.24 3 17911 103479 64377339
Hepatosplenomegaly 18.91 16.24 14 17900 5329 64475489
Injection site pain 18.78 16.24 4 17910 111404 64369414
Tubulointerstitial nephritis 18.70 16.24 32 17882 30877 64449941
Disseminated tuberculosis 18.69 16.24 12 17902 3633 64477185
Trimethylaminuria 18.63 16.24 5 17909 156 64480662
Progressive multifocal leukoencephalopathy 18.42 16.24 24 17890 18208 64462610
Hypercholesterolaemia 18.35 16.24 22 17892 15351 64465467
Hepatic cirrhosis 18.30 16.24 29 17885 26269 64454549
Diabetes mellitus 18.30 16.24 50 17864 66424 64414394
Ear malformation 18.27 16.24 3 17911 6 64480812
Infected vasculitis 18.27 16.24 3 17911 6 64480812
Drug abuse 18.18 16.24 7 17907 132367 64348451
Death 18.05 16.24 71 17843 482634 63998184
Synovitis 17.89 16.24 3 17911 99087 64381731
Oligohydramnios 17.81 16.24 11 17903 3113 64477705
Liver function test abnormal 17.69 16.24 46 17868 59355 64421463
Pain in extremity 17.67 16.24 36 17878 303049 64177769
Epistaxis 17.65 16.24 3 17911 98128 64382690
Subchondral insufficiency fracture 17.50 16.24 4 17910 63 64480755
Hepatitis A 17.17 16.24 7 17907 817 64480001
Varices oesophageal 17.17 16.24 13 17901 5117 64475701
Nephropathy 17.17 16.24 16 17898 8370 64472448
Fat tissue increased 17.02 16.24 7 17907 836 64479982
Acute kidney injury 16.98 16.24 195 17719 449045 64031773
Opportunistic infection 16.79 16.24 10 17904 2652 64478166
Lower respiratory tract infection 16.78 16.24 3 17911 94611 64386207
Infection 16.73 16.24 16 17898 184864 64295954
Liver disorder 16.60 16.24 42 17872 53309 64427509
Segmented hyalinising vasculitis 16.46 16.24 4 17910 83 64480735
Chronic kidney disease 16.38 16.24 44 17870 57875 64422943
Drug level decreased 16.32 16.24 18 17896 11485 64469333
Hepatitis B 16.29 16.24 15 17899 7730 64473088
Gene mutation 16.29 16.24 9 17905 2073 64478745

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC J05AR02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EPC N0000175462 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
FDA MoA N0000193954 Cytochrome P450 1A1 Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Toxic amblyopia contraindication 965003
Myositis contraindication 26889001 DOID:633
Hepatic failure contraindication 59927004
Pancreatitis contraindication 75694006 DOID:4989
Large liver contraindication 80515008
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Disorder of muscle contraindication 129565002 DOID:423
Steatosis of liver contraindication 197321007
Acute pancreatitis contraindication 197456007 DOID:2913
Chronic pancreatitis contraindication 235494005
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Hypertriglyceridemia contraindication 302870006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
HLA-B 5701 Positive Status contraindication
Drug Resistance to Anti-retroviral Therapy contraindication




🐢 Veterinary Drug Use

None

🐢 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.09 acidic
pKa2 5.64 Basic
pKa3 0.88 Basic
pKa4 0.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR EC50 5.28 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein EC50 5.28 WOMBAT-PK
Reverse transcriptase Enzyme IC50 6.89 CHEMBL

External reference:

IDSource
4029879 VUID
N0000180961 NUI
D00891 KEGG_DRUG
188062-50-2 SECONDARY_CAS_RN
168146-84-7 SECONDARY_CAS_RN
190521 RXNORM
C0663655 UMLSCUI
CHEBI:421707 CHEBI
1KX PDB_CHEM_ID
CHEMBL1380 ChEMBL_ID
CHEMBL2106686 ChEMBL_ID
CHEMBL4303288 ChEMBL_ID
DB01048 DRUGBANK_ID
CHEMBL1200619 ChEMBL_ID
C106538 MESH_SUPPLEMENTAL_RECORD_UI
441300 PUBCHEM_CID
11152 IUPHAR_LIGAND_ID
7544 INN_ID
WR2TIP26VS UNII
14010 MMSL
191490 MMSL
30504 MMSL
66957 MMSL
7865 MMSL
d04376 MMSL
007687 NDDF
007688 NDDF
4021139 VANDF
4024130 VANDF
4029879 VANDF
116084008 SNOMEDCT_US
387005008 SNOMEDCT_US
412074007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0121-0897 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0378-4105 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6523 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0904-6874 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Human Prescription Drug Label 1 31722-557 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 31722-562 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-402 TABLET, FILM COATED 600 mg ORAL ANDA 29 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-430 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Abacavir and Lamivudine HUMAN PRESCRIPTION DRUG LABEL 2 42291-115 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 49702-206 TABLET, FILM COATED 600 mg ORAL NDA 27 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 49702-206 TABLET, FILM COATED 600 mg ORAL NDA 27 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 49702-217 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 49702-217 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-221 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-221 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-222 SOLUTION 20 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-222 SOLUTION 20 mg ORAL NDA 26 sections
Triumeq HUMAN PRESCRIPTION DRUG LABEL 3 49702-231 TABLET, FILM COATED 600 mg ORAL NDA 27 sections
Triumeq HUMAN PRESCRIPTION DRUG LABEL 3 49702-231 TABLET, FILM COATED 600 mg ORAL NDA 27 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 50268-049 TABLET 300 mg ORAL ANDA 27 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 50268-049 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51079-204 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0627 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 53808-0767 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 53808-0811 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 53808-0990 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 54868-5600 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE HUMAN PRESCRIPTION DRUG LABEL 3 57297-286 TABLET 300 mg ORAL ANDA 29 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 64380-717 TABLET 300 1 ORAL ANDA 25 sections
Abacavir Human Prescription Drug Label 1 64980-405 SOLUTION 20 mg ORAL ANDA 27 sections